<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-1740199-B1" country="EP" doc-number="1740199" kind="B1" date="20140101" family-id="34074040" file-reference-id="311102" date-produced="20180822" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146553787" ucid="EP-1740199-B1"><document-id><country>EP</country><doc-number>1740199</doc-number><kind>B1</kind><date>20140101</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-05735913-A" is-representative="NO"><document-id mxw-id="PAPP154827710" load-source="docdb" format="epo"><country>EP</country><doc-number>05735913</doc-number><kind>A</kind><date>20050428</date><lang>EN</lang></document-id><document-id mxw-id="PAPP220007994" load-source="docdb" format="original"><country>EP</country><doc-number>05735913.5</doc-number><date>20050428</date></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140455153" ucid="IL-16167204-A" load-source="docdb"><document-id format="epo"><country>IL</country><doc-number>16167204</doc-number><kind>A</kind><date>20040429</date></document-id></priority-claim><priority-claim mxw-id="PPC140446466" ucid="IL-2005000443-W" linkage-type="W" load-source="docdb"><document-id format="epo"><country>IL</country><doc-number>2005000443</doc-number><kind>W</kind><date>20050428</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130712</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1988123950" load-source="docdb">A61K  38/20        20060101AFI20051116BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1988129111" load-source="docdb">A61P  25/02        20060101ALI20051116BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1988114916" load-source="docdb" scheme="CPC">A61K  38/204       20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132193845" lang="DE" load-source="patent-office">IL6R/IL6 CHIMÄRE ZUR BEHANDLUNG VON DURCH CHEMOTHERAPIE AUSGELÖSTER PERIPHERER NEUROPATHIE</invention-title><invention-title mxw-id="PT132193846" lang="EN" load-source="patent-office">IL6R/IL6 CHIMERA FOR THERAPY OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY</invention-title><invention-title mxw-id="PT132193847" lang="FR" load-source="patent-office">CHIMERE IL6R/IL6 POUR TRAITEMENT D'UNE NEUROPATHIE PERIPHERIQUE INDUITE PAR UNE CHIMIOTHERAPIE</invention-title><citations><non-patent-citations><nplcit><text>BIOLOGICAL ABSTRACTS, vol. 22, Philadelphia, PA, US; abstract no. 2976, DAVIS ET AL: "A randomized, double-blinded, placebo*controlled phase II trial to determine the safety and efficacy of AM424 (emfilermin, rhLIF) in the prevention of chemotherapy-induced peripheral neuropathy (CIPN)"</text><sources><source mxw-id="PNPL66791678" load-source="docdb" name="EXA"/></sources></nplcit></non-patent-citations></citations></technical-data><parties><applicants><applicant mxw-id="PPAR918168737" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>YEDA RES &amp; DEV</last-name><address><country>IL</country></address></addressbook></applicant><applicant mxw-id="PPAR918135690" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>YEDA RESEARCH AND DEVELOPMENT CO., LTD.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR918134550" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>REVEL MICHEL</last-name><address><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR918150178" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>REVEL, MICHEL</last-name></addressbook></inventor><inventor mxw-id="PPAR918997897" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>REVEL, MICHEL</last-name><address><street>Weizmann Institute Bet Brazil 5</street><city>76100 Rehovot</city><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR918142769" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>CHEBAT JUDITH</last-name><address><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR918161624" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>CHEBAT, JUDITH</last-name></addressbook></inventor><inventor mxw-id="PPAR918997898" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>CHEBAT, JUDITH</last-name><address><street>Rehov Carmel 14/appt 5</street><city>76286 Rehovot</city><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR918165603" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>KRUG HAGIT</last-name><address><country>IL</country></address></addressbook></inventor><inventor mxw-id="PPAR918160778" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>KRUG, HAGIT</last-name></addressbook></inventor><inventor mxw-id="PPAR918997899" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>KRUG, HAGIT</last-name><address><street>5 David Hamelech Street</street><city>59562. Bat Yam</city><country>IL</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR918997901" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>YEDA RESEARCH AND DEVELOPMENT CO., LTD.</last-name><iid>100988765</iid><address><street>The Weizmann Institute of Science P.O. Box 95</street><city>76100 Rehovot</city><country>IL</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR918997900" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Grünecker, Kinkeldey, Stockmair &amp; Schwanhäusser Anwaltssozietät</last-name><iid>100060488</iid><address><street>Leopoldstrasse 4</street><city>80802 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="IL-2005000443-W"><document-id><country>IL</country><doc-number>2005000443</doc-number><kind>W</kind><date>20050428</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2005105134-A1"><document-id><country>WO</country><doc-number>2005105134</doc-number><kind>A1</kind><date>20051110</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS548979618" load-source="docdb">AT</country><country mxw-id="DS548867999" load-source="docdb">BE</country><country mxw-id="DS548885360" load-source="docdb">BG</country><country mxw-id="DS548830114" load-source="docdb">CH</country><country mxw-id="DS548980377" load-source="docdb">CY</country><country mxw-id="DS548979619" load-source="docdb">CZ</country><country mxw-id="DS548990185" load-source="docdb">DE</country><country mxw-id="DS548868000" load-source="docdb">DK</country><country mxw-id="DS548980378" load-source="docdb">EE</country><country mxw-id="DS548986754" load-source="docdb">ES</country><country mxw-id="DS548885361" load-source="docdb">FI</country><country mxw-id="DS548885362" load-source="docdb">FR</country><country mxw-id="DS548868001" load-source="docdb">GB</country><country mxw-id="DS548868002" load-source="docdb">GR</country><country mxw-id="DS548980379" load-source="docdb">HU</country><country mxw-id="DS548830116" load-source="docdb">IE</country><country mxw-id="DS548868003" load-source="docdb">IS</country><country mxw-id="DS548885363" load-source="docdb">IT</country><country mxw-id="DS548980380" load-source="docdb">LI</country><country mxw-id="DS548990186" load-source="docdb">LT</country><country mxw-id="DS548979620" load-source="docdb">LU</country><country mxw-id="DS548990187" load-source="docdb">MC</country><country mxw-id="DS548979621" load-source="docdb">NL</country><country mxw-id="DS548979714" load-source="docdb">PL</country><country mxw-id="DS548986756" load-source="docdb">PT</country><country mxw-id="DS548979715" load-source="docdb">RO</country><country mxw-id="DS548979716" load-source="docdb">SE</country><country mxw-id="DS548990188" load-source="docdb">SI</country><country mxw-id="DS548830117" load-source="docdb">SK</country><country mxw-id="DS548982480" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>AL</country></ep-extended-state-data><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>HR</country></ep-extended-state-data><ep-extended-state-data><country>LV</country></ep-extended-state-data><ep-extended-state-data><country>MK</country></ep-extended-state-data><ep-extended-state-data><country>YU</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63957413" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><heading id="h0001"><b>FIELD OF THE INVENTION</b></heading><p id="p0001" num="0001">The present invention is in the field of chemotherapy-induced neuropathy. In particular, it relates to the use of an IL-6R/IL-6 chimera in the manufacture of a medicament for the treatment and/or prevention of chemotherapy induced neuropathy, wherein the chemotherapy agent is a vinca alkaloid.</p><heading id="h0002"><b>BACKGROUND OF THE INVENTION</b></heading><p id="p0002" num="0002">Peripheral neuropathy is a complex of disorders of the peripheral nervous system resulting from damage to the nerve or to the myelin sheath. The damage is long lasting, usually outlasting the injury that initiates it.<br/>
Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potential disabling side effect of many cytotoxic drugs. Chemotherapy-induced neuropathy is related to cumulative dose or dose-intensities (<nplcit id="ncit0001" npl-type="s"><text>Verstappen et al. 2003 Drugs 63:1549-63</text></nplcit>).</p><p id="p0003" num="0003">The vinca-alkaloids (e.g. vincristine and vinblastine), platinum-based compounds (e.g. cisplatin) and taxanes (paclitaxel and docetaxel) are amongst the most important drugs inducing peripheral neurotoxicity (<nplcit id="ncit0002" npl-type="s"><text>Visovsky C. Cancer Invest. 2003 Jun; 21(3): 439-51</text></nplcit>), <nplcit id="ncit0003" npl-type="s"><text>Quasthoff S, Hartung HP J Neurol. 2002 Jan; 249(1): 9-17</text></nplcit>. Review). These drugs are widely used for treatment of various malignancies such as ovarian, breast cancer, and haematological cancers (<nplcit id="ncit0004" npl-type="s"><text>Verstappen et al. 2003 Drugs 63(15): 1549</text></nplcit>).</p><p id="p0004" num="0004">Vincristine-driven neuropathy is mainly characterized by motor and sensory insufficiency (mixed type of neuropathy). Whilst the underlying mechanism is not fully understood as yet, it has been described to involve an alteration of anterograde axonal transport, ultimately leading to axonal degeneration. Up to now, treatment of vincristine-driven neuropathy is only palliative, as no efficient therapy has been developed so far.</p><p id="p0005" num="0005">Currently, CIPN is alleviated by dose reduction, which may compromise the efficacy of the chemotherapy treatment. Patients who already have neuropathic symptoms due to diabetes mellitus, hereditary neuropathies or early treatment with neurotoxic chemotherapy are thought to be more vulnerable for the development of CIPN.<br/>
<!-- EPO <DP n="2"> -->In general, treatment of peripheral neuropathy is symptomatic and has no beneficial effect underlying damage to the nerves (<nplcit id="ncit0005" npl-type="s"><text>Peltier AC, Russell JW. Recent advances in drug-induced neuropathies. Curr Opin Neurol. 2002 Oct; 15(5): 633-8</text></nplcit>). For example, pyridoxine (vitamin B6) is used as a method of nutritional support following peripheral nerve damage, antioxidants (e.g. gamma-linoleic acid, alphalipoic acid, and PKC inhibitors and aldose reductase inhibitors.) are used to eliminate toxins which may contribute to peripheral neuropathy, anticonvulsant are used to suppress the pain symptoms. Attempts to prevent vincristine-neuropathy using putative neuroprotective agents such as vitamin B1, vitamin B12, glutamate (<nplcit id="ncit0006" npl-type="s"><text>Boyle et al. J Pharmacol Exp Ther. 1996 Oct; 279(1): 410-5</text></nplcit>.), isoaxonine (<nplcit id="ncit0007" npl-type="s"><text>Le Quesne et al., J Neurol Neurosurg Psychiatry. 1985 Sep; 48(9): 933-5</text></nplcit>.), gangliosides or nerve growth factor (<nplcit id="ncit0008" npl-type="s"><text>Hayakawa et al., Life Sci. 1994; 55(7): 519-25</text></nplcit>. 4; <nplcit id="ncit0009" npl-type="s"><text>Lewis et al. Exp Neurol. 1993 Nov; 124(1): 73-88</text></nplcit>.) showed limited success.</p><p id="p0006" num="0006">Interleukin (IL)-6 is a pleiotropic cytokine that not only affects the immune system, but also acts in other biological systems and many physiological events in various organs. In a target cell, IL-6 can simultaneously generate functionally distinct or sometimes contradictory signals through its receptor complex, IL-6Ralpha and gp130. The final physiological output can be thought of as a consequence of the orchestration of the diverse signaling pathways generated by a given ligand. This concept, the signal orchestration model, may explain how IL-6 can elicit proinflammatory or antiinflammatory effects, depending on the in vivo environmental circumstances. Elucidation of the molecular mechanisms underlying this issue is a challenging subject for future research (Jones et al. 2001, <nplcit id="ncit0010" npl-type="s"><text>Heinrich et al. 2003 Biochem Journal 374, 1-20</text></nplcit>). The functional properties of IL-6 are extremely varied and this is reflected by the terminology originally used to describe this cytokine (Horst Ibelgaufts' COPE: Cytokines Online Pathfinder Encyclopaedia).</p><p id="p0007" num="0007">The biological activities of IL-6 are mediated by a membrane receptor system comprising two different proteins one named IL-6 Receptor (IL-6R or gp80 reviewed by<!-- EPO <DP n="3"> --> <nplcit id="ncit0011" npl-type="s"><text>Jones et al. FASEB J. 2001 Jan; 15(1): 43-58</text></nplcit>. Review.) and the other gp130 (reviewed by <nplcit id="ncit0012" npl-type="s"><text>Hirano et al Stem Cells. 1994 May; 12(3):262-77</text></nplcit>. Review). Soluble forms of IL-6R (sIL-6R), corresponding to the extracellular domain of gp80, are natural products of the human body found as glycoproteins in blood and in urine (<nplcit id="ncit0013" npl-type="s"><text>Novick et al, J Chromatogr. 1990 Jun 27;510:331-7</text></nplcit>, and<nplcit id="ncit0014" npl-type="s"><text> Cytokine. 1992 Jan;4(1):6-11</text></nplcit>.). An exceptional property of sIL-6R molecules is that they act as potent agonists of IL-6 on many cell types including human cells (<nplcit id="ncit0015" npl-type="s"><text>Taga et al, Cell. 1989 Aug 11;58(3):573-81</text></nplcit>. <nplcit id="ncit0016" npl-type="s"><text>Novick et al. 1992 Jan;4(1):6-11</text></nplcit>). Even without the intracytoplasmic domain of gp80, sIL-6R is still capable of triggering the dimerization of gp130 in response to IL-6, which in turn mediates the subsequent IL-6-specific signal transduction and biological effects (<nplcit id="ncit0017" npl-type="s"><text>Murakami Science. 1993 Jun 18;260(5115):1808-10</text></nplcit>.). sIL-6R has two types of interaction with gp130 both of which are essential for the IL-6 specific biological activities (<nplcit id="ncit0018" npl-type="s"><text>Halimi et al., Eur Cytokine Netw. 1995 May-Jun;6(3):135-43</text></nplcit>), and the active IL-6 receptor complex was proposed to be a hexameric structure formed by two gp130 chains, two IL-6R and two IL-6 ligands (Ward et al., 1994;<nplcit id="ncit0019" npl-type="s"><text> Paonessa et al, EMBO J. 1995 May 1;14(9):1942-51</text></nplcit>.).</p><p id="p0008" num="0008">In contrast to the expression of the cognate IL-6R which has a limited cellular distribution (reviewed by Jones et al. 2001), expression of the trans-membrane-spanning gp130 is found in almost all organs, including heart, kidney, spleen, liver, lung, placenta, and brain (<nplcit id="ncit0020" npl-type="s"><text>Saito et al J Immunol. 1992 Jun 15;148(12):4066-71</text></nplcit>).</p><p id="p0009" num="0009">In vitro, there are many different examples, which show that IL-6 alone does not induce a specific activity unless the soluble IL-6R is administered. For example, IL-6 induces osteoclast formation in co-cultures of mouse bone marrow and osteoblastic cells, only when combined with the sIL-6R (reviewed by Jones et al. 2001). Also, although many neuronal cells are capable of producing IL-6, they remain unresponsive to stimulation by IL-6 itself. Differentiation and survival of neuronal cells can, however, be mediated through the action of sIL-6R (<nplcit id="ncit0021" npl-type="s"><text>Hirota J Exp Med. 1996 Jun 1;183(6):2627-34</text></nplcit>., Martz 1998).<!-- EPO <DP n="4"> --></p><p id="p0010" num="0010">The circulating concentrations of sIL-6R (agonist) in normal subjects are relatively high and comparable to those of soluble gp130 of above 10 ng/ml, a natural antagonist of IL-6, (<nplcit id="ncit0022" npl-type="s"><text>Corbi et al 2000 Eur J Cardiotherac Surg. 18 (1):98-103</text></nplcit>, <nplcit id="ncit0023" npl-type="s"><text>Disthabanchong et al. Clin Nephrol. 2002 Oct;58(4):289-95</text></nplcit>). In contrast, the circulating concentrations of IL-6 are about or below 10 pg/ml (<nplcit id="ncit0024" npl-type="s"><text>Kado et al. 1999 Acta Diabetol. Jun 36 (1-2)67-72</text></nplcit>, Corbi et al 2000. Thus the effect of IL-6 administration in vivo, alone, without co-administration with sIL-6R in disease may or may not be effective and depends on the concentration of the soluble agonist/antagonist in a particular disease and in a particular location in the body.</p><p id="p0011" num="0011">Chimeric molecules linking the soluble IL-6 receptor and IL-6 together have been described (<nplcit id="ncit0025" npl-type="s"><text>Chebath et al.Eur Cytokine Netw. 1997 Dec;8(4):359-65</text></nplcit>.). They have been designated IL-6R/IL-6 chimera. The chimeric IL-6R/IL-6 molecules were generated by fusing the entire coding regions of the cDNAs encoding the soluble IL-6 receptor (sIL-6R) and IL-6. Recombinant IL-6R/IL-6 chimera was produced in CHO cells (<nplcit id="ncit0026" npl-type="s"><text>Chebath et al, Eur Cytokine Netw. 1997</text></nplcit>, <patcit id="pcit0001" dnum="WO9902552A"><text>WO99/02552</text></patcit>). The IL-6R/IL-6 binds with a higher efficiency to the gp130 chain in vitro than does the mixture of IL-6 with sIL-6R (<nplcit id="ncit0027" npl-type="s"><text>Kollet et al, Blood. 1999 Aug 1;94(3):923-31</text></nplcit>).</p><p id="p0012" num="0012">MBP and P0 proteins are normally induced during the final postnatal maturation of Schwann cells, and they are re-induced during nerve regeneration. The IL-6R/IL-6 chimera has been shown to induce the expression of myelin basic protein (MBP) and P0 gene products MBP and P0 RNAs and proteins in cultures of dorsal root ganglia (DRG) from 14 day old mouse embryos (<nplcit id="ncit0028" npl-type="s"><text>FEBS Lett. 1999 Aug 27;457(2):200-4</text></nplcit>. et al., 1999). In addition, the expression of MBP and P0 was found to be induced by IL6R/IL6 chimera also in cultured tumor cells of neural crest origin. In both cases, the induction of MBP and P0 genes by IL6R/IL6, chimera in normal embryonic Schwann cells precursors and in tumor cells of neural crest origin, is associated with a down-regulation of Pax-3 (<nplcit id="ncit0029" npl-type="s"><text>Kamaraju et al JBC 2002 277 15132</text></nplcit>, <nplcit id="ncit0030" npl-type="s"><text>Slutsky et al. J Biol Chem. 2003 Mar 14;278(11):8960-8</text></nplcit>, <nplcit id="ncit0031" npl-type="s"><text>Haggiag et al, J. Neurosci. Res. 2001</text></nplcit>).<!-- EPO <DP n="5"> --></p><p id="p0013" num="0013">The stimulatory effect of the gp130 activator IL6R/IL6 on myelination in vivo was demonstrated in a rat model of sciatic nerve transection. Injections of IL6R/IL6 led to a 7-fold increase of the number of myelinated fibers in the regenerating nerve (<nplcit id="ncit0032" npl-type="s"><text>Haggiag et al, J. Neurosci. Res. 2001</text></nplcit>).</p><p id="p0014" num="0014">The therapeutic effect of recombinant IL-6 alone without the soluble IL-6R in an animal model of diabetes-induced peripheral neuropathy has been disclosed in patent application <patcit id="pcit0002" dnum="WO03033015A"><text>WO03033015</text></patcit>. However, it is uncertain whether IL6R/IL-6 chimera alone or IL-6 alone or together with sIL-6R, are capable of a beneficial effect in peripheral neuropathy caused by chemotherapy. In fact, recombinant leukemia inhibitor factor (LIF), another gp130 activator, was tested in clinical trials for preventing peripheral neuropathy caused by carboplatin/paclitaxel (<nplcit id="ncit0033" npl-type="s"><text>Davis et al. Proc Am Soc Clin Oncol 22: page 740, 2003, abstr 2976</text></nplcit>) and the results indicated that LIF was ineffective at preventing CIPN at the doses and regime tested.</p><p id="p0015" num="0015"><nplcit id="ncit0034" npl-type="s"><text>HAYAKAWA et al (1994, LIFE SCIENCES, vol. 55, no. 7, 519-525</text></nplcit>) disclose the use of NGF for the treatment of chemotherapy induced peripheral neuropathy.</p><p id="p0016" num="0016">Therefore, new drugs/strategies for preventing/treating peripheral neuropathy caused by chemotherapy agents are thus needed.</p><heading id="h0003"><b>SUMMARY OF THE INVENTION</b></heading><p id="p0017" num="0017">The present invention relates to the following items:
<ol><li>1. Use of an IL6R/IL6 chimera, or a mutein thereof, in the manufacture of a medicament for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN), wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</li><li>2. The use according to item 1, wherein the peripheral neuropathy is caused by vinblastine, vincristine or a mixture thereof.<!-- EPO <DP n="6"> --><!-- EPO <DP n="7"> --></li><li>3. The use according to item 1 or 2, wherein the IL6R/IL6 chimera or mutein thereof is glycosylated at one or more sites.</li><li>4. The use according to items 1 or 2, wherein the IL6R/IL6 chimera or mutein thereof is non-glycosylated.</li><li>5. The use according to any of the preceding items, wherein the mutein comprises at least one moiety attached to one or more functional groups.</li><li>6. The use according to item 5, wherein the moiety is a polyethylene moiety.</li><li>7. The use according to any one of items 1 to 6, wherein the medicament comprises a cell expressing an IL6R/IL6 chimera or a mutein thereof.</li><li>8. The use according to any one of items 1 to 7, wherein the medicament comprises an expression vector comprising the coding sequence of an IL6R/IL6 chimera or mutein thereof.</li><li>9. The use according to item 8, wherein the vector is a lentiviral vector.</li><li>10. The use of any of items 1 to 9, wherein the medicament optionally comprises a pharmaceutically acceptable carrier.</li><li>11. The use of item 10, wherein the patient is a high-risk patient.</li><li>12. The use of item 11, wherein the high-risk patient is selected from patients suffering from diabetes, AIDS, hereditary neuropathies and patients subjected to early treatment with neurotoxic drugs.</li><li>13. The use of any of items 10 to 12, wherein the administration route of the medicament is selected from intraliver, intradermal, intraplantar, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, epidural, topical, and intranasal.</li><li>14. Use of an IL6R/IL6 chimera or a mutein thereof, optionally together with a pharmaceutically acceptable carrier, in the manufacture of a medicament for increasing the dose of a chemotherapeutic agent in a patient, wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or<!-- EPO <DP n="8"> --> more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</li><li>15. The use according to item 14, wherein the medicament is administered either before, during, and/or after the chemotherapy agent.</li><li>16. A pharmaceutical composition comprising a combination of an IL6R/IL6 chimera or a mutein thereof and a chemotherapeutic agent wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</li><li>17. The pharmaceutical composition according to item 16, wherein the vinca alkaloid is selected from vinblastine, vincristine or a mixture thereof.</li><li>18. The pharmaceutical composition according to item 16 or 17, further comprising an additional drug selected from antioxidants, PKC inhibitors and neuroprotective agents.</li><li>19. The pharmaceutical composition according to item 18, wherein the additional drug is selected from glutamate, pyridoxine, gamma-linoleic acid, vitamin B1, vitamin B2, isoaxonine, ganglioside and NGF.</li><li>20. An IL6R/IL6 chimera, or a mutein thereof, for use in the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN), wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</li><li>21. An an IL6R/IL6 chimera, or a mutein thereof, for use in increasing the dose of a chemotherapeutic agent in a patient, wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by way of amino acid deletion, insertion, addition or substitution of one or more amino acid<!-- EPO <DP n="9"> --> residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130</li></ol></p><heading id="h0004"><b>BRIEF DESCRIPTION OF THE DRAWINGS</b></heading><p id="p0018" num="0018"><figref idrefs="f0001">Figure 1</figref> shows in vitro neuroprotection against vincristine by activation of IL-6 signaling. (A) Outgrowing axonal network stained for βIII-tubulin in DRG cultures after 7 days in NGF-containing medium. (B) Similar culture treated for the last 2 days with 10 nM vincristine. Note the extensive neurodegeneration. (C) Similar culture treated for the last 2 days with vincristine and 200 ng/ml IL-6R/IL-6 . Significant protection of the axonal network is observed. Panels A-C are at same magnification; size bar: 100 µm. (D) Outgrowth of DRG cultured in NGF-containing medium for 10 days, with 10 nM vincristine added for the last 5 days. Cells undergoing apoptosis are visualized by staining with antibodies against activated caspase-3. (E) Similar culture in which 200 ng/ml IL-6R/IL-6 was added together with vincristine. No apoptosis is observed.<!-- EPO <DP n="10"> --> (D', E') same fields as D, E under light phase contrast. Panels D-E' at same magnification; size bar: 100 µm.</p><p id="p0019" num="0019"><figref idrefs="f0002">Figure 2</figref> shows stimulation of regeneration following vincristine intoxication. (A) Outgrowing axonal network stained for βIII-tubulin in DRG cultures after 16 days in NGF-containing medium. (B) Similar culture supplemented with 200 ng/ml IL-6R/IL-6 from day 5 to 16. (C) Culture as in A, treated with 5 nM vincristine from day 5 to 10. After removal of the drug, the culture was continued for 6 more days. (D) Culture as in A, treated with 5 nM vincristine from day 5 to 10, and then with IL-6R/IL-6 for 6 more days following the removal of the drug. (E) DRG culture as in C, with vincristine from day 5 to 10, and further culture 6 days without the drug. Outgrowth stained for GFAP. (F) Culture as in D, with vincristine from day 5 to 10, and further culture 6 days with IL-6R/IL-6. Note the regrowth of GFAP positive cells. Panels A-D and E-F are at the same magnification respectively; size bar: 100 µm.</p><heading id="h0005"><b>DETAILED DESCRIPTION OF THE INVENTION</b></heading><p id="p0020" num="0020">The invention relates to the use of an IL6R/IL6 chimera, or a mutein thereof, for the manufacture of a medicament for the prevention of Chemotherapy Induced Peripheral Neuropathy (CIPN), wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp 130.</p><p id="p0021" num="0021">Currently, treatment of peripheral neuropathy is symptomatic and has no beneficial effect underlying damage to the nerves. Typically, CIPN is alleviated by dose reduction, which may compromise the efficacy of treatment.</p><p id="p0022" num="0022">Thus, the present invention presents a substantial progress, namely, IL6R/IL6 chimera can be used together with the chemotherapeutic agent to prevent chemotherapy-induced damage development. Moreover, it was shown that IL6R/IL6 chimera administered in<!-- EPO <DP n="11"> --> vitro after development of chemotherapy-induced damage was able to restore neural tissue.</p><p id="p0023" num="0023">Therefore, the medicament is for the treatment and/or prevention of CIPN caused by a wide range of chemotherapy agents selected from vinca-alkaloids (e.g. vincristine and vinblastine).</p><p id="p0024" num="0024">The invention is based on the findings that co-administration of IL6R/IL6 chimera with vincristine was very efficient at preventing induction of axonal degeneration by vincristine in vitro.</p><p id="p0025" num="0025">For example, neuronal outgrowth was stimulated in cultures of dorsal root ganglia (DRG) from mouse embryos (day E17) by addition of Nerve Growth Factor (NGF). Subsequently the cultures were exposed to vincristine, which induces a progressive axonal degeneration process due to caspase-3 activation. After 2 days of vincristine treatment caspase-3 activation and a considerable loss of axons in the DRG neuronal outgrowth and were observed (<figref idrefs="f0001">Fig. 1</figref>, panels B versus A and D). However, unexpectedly, when IL-6R/IL-6 was present during the vincristine treatment there was virtually no caspase-3 activation (<figref idrefs="f0001">Fig. 1</figref>, panels E versus D). It was also observed that IL-6R/IL-6 prevented axonal degeneration (<figref idrefs="f0001">Fig. 1</figref>, panels C versus B).</p><p id="p0026" num="0026">The invention is based also on the findings that the treatment with IL6R/IL6 chimera efficiently restored neural tissue even if added after the neural damage by vincristine was already established.</p><p id="p0027" num="0027">For example, DRG of E18.5 embryos from IL-6 deficient mice (IL-6-/-) cultures in which the axonal network was formed in the presence of NGF for 5 days were either continued for another 11 days without or with IL-6R/IL-6 (<figref idrefs="f0002">Figure 2</figref>, panel A and B, respectively), or treated for 5 days by vincristine at which time vincristine was removed and culture<!-- EPO <DP n="12"> --> continued for 6 more days (<figref idrefs="f0002">Figure 2</figref>, panels C-F). It was observed that the extensive degeneration of the axonal network was still present 6 days after vincristine was removed (<figref idrefs="f0002">Figure 2</figref>, panel C) but when IL-6R/IL-6 was added after vincristine removal a significant re-growth of the axons was observed (<figref idrefs="f0002">Figure 2</figref>, panel D). In parallel cultures immunostained for glial fibrillary acidic protein (GFAP), the addition of IL-6R/IL-6 was seen to produce a marked re-growth of glial cells (<figref idrefs="f0002">Figure 2</figref>, panel F) as compared to the control cultures 6 days after vincristine removal (<figref idrefs="f0002">Figure 2</figref>, panel E).<br/>
In several similar experiments, the curative effects of IL-6R/IL-6 were seen in DRG cultures from IL-6+/+ mice, and were apparent already two days after IL-6R/IL-6 addition (not shown).</p><p id="p0028" num="0028">Altogether, the results obtained unequivocally demonstrate the preventive and/or curative therapeutic value of IL6R/IL6 in CIPN.</p><p id="p0029" num="0029">The IL6R/IL6 chimera, or mutein thereof, according to the invention, can be for example non-glycosylated or can be glycosylated at one or more sites.<br/>
In a preferred embodiment, the mutein may comprise at least one moiety, such as a polyethylene moiety, attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.<br/>
In another embodiment, the IL-6R/IL6 chimera or mutein thereof according to the invention, may be expressed by a cell, or by an expression vector comprising the coding sequence of an IL6R/IL6 chimera or a mutein thereof. In a preferred embodiment, the vector is a lentiviral vector.</p><p id="p0030" num="0030">The invention also relates to an IL6R/IL6<!-- EPO <DP n="13"> --> chimera or a mutein thereof, optionally together with a pharmaceutically acceptable carrier, in the manufacture of a medicament for increasing the dose of a chemotherapeutic agent in a patient, wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.<!-- EPO <DP n="14"> --></p><p id="p0031" num="0031">In a preferred embodiment, the patient in need is a high risk patient, such as those patients having suffered from diabetes mellitus already for a prolonged period of time, patients who already have neuropathic symptoms due to AIDS and, patients with hereditary neuropathies or subjected to early treatment with neurotoxic chemotherapy etc.</p><p id="p0032" num="0032">In addition, the invention relates to a pharmaceutical composition comprising a combination of IL6R/IL6 chimera or mutein thereof, and a chemotherapeutic agent, wherein the chemotherapy agent is a vinca alkaloid. In one embodiment a preferred chemotherapeutic agent was vincristine.<br/>
In a more preferred embodiment, the pharmaceutical composition further comprises a an additional drug such as for example, pyridoxine (vitamin B6), antioxidants (e.g. gamma-linoleic acid, alphalipoic acid, PKC inhibitors and aldose reductase inhibitors, anticonvulsant are used to suppress the pain symptoms, neuroprotective agents such as<!-- EPO <DP n="15"> --> vitamin B1, vitamin B12, glutamate (Boyle et al., 1996), isoaxonine (Le Quesne et al., 1985), gangliosides or nerve growth factor.</p><p id="p0033" num="0033">An "IL-6R/IL-6 chimera" (also called "IL-6R/IL-6" or "IL-6 chimera"), as used herein, is a chimeric molecule comprising a soluble part of gp130 fused to all or a biologically active fraction of interleukin-6. The moieties of the chimeric protein can be fused directly to one another, or they can be linked by any suitable linker, such as a disulfide bridge or a polypeptide linker. The linker may be a short linker peptide which can be as short as 1 to 3 amino acid residues in length or longer, for example, 13 or 18 amino acid residues in length. Said linker may be a tripeptide of the sequence E-F-M (Glu-Phe-Met), for example, or a 13-amino acid linker sequence comprising Glu-Phe- Gly-Ala-Gly-Leu-Val-Leu-Gly-Gly-Gln-Phe-Met introduced between the amino acid sequence of the soluble IL-6 receptor gp 130 and the IL-6 sequence. Examples of IL-6R/IL-6 chimera are known in the art and have been described in detail e. g. in <patcit id="pcit0003" dnum="WO9902552A"><text>WO 99/02552</text></patcit> or <patcit id="pcit0004" dnum="WO9732891A"><text>WO 97/32891</text></patcit>.</p><p id="p0034" num="0034">The terms "treating/curing and preventing" as used herein should be understood as preventing, inhibiting, attenuating, ameliorating or reversing one or more symptoms or cause (s) of chemotherapy neuropathy, as well as symptoms, diseases or complications accompanying chemotherapy neuropathy. When "treating/curing" chemotherapy neuropathy, the substances according to the invention are given after onset of the disease, "prevention" relates to administration of the substances before any signs of disease can be noted in the patient.</p><p id="p0035" num="0035">The term "chemotherapy neuropathy" relates to any form of chemotherapy neuropathy, or to one or more symptom (s) or disorder (s) accompanying or caused by chemotherapy neuropathy, or complications of chemotherapy affecting nerves as described in detail in the introduction above.</p><p id="p0036" num="0036">The term "dose" relates to the quantity to be administered at one time, such as a specified amount of medication.<!-- EPO <DP n="16"> --></p><p id="p0037" num="0037">The term "dosage" relates to the determination and regulation of the size, frequency, and number of doses.</p><p id="p0038" num="0038">As used herein the term "muteins" refers to analogs of an IL6R/IL6 chimera, in which one or more of the amino acid residues of the naturally occurring components of IL6R/IL6 chimera are replaced by different amino acid residues, or are deleted, or one or more amino acid residues are added to the original sequence of an IL6R/IL6 chimera, without changing considerably the activity of the resulting products as compared with the original IL6R/IL6 chimera. These muteins are prepared by known synthesis and/or by site-directed mutagenesis techniques, or any other known technique suitable therefore.</p><p id="p0039" num="0039">Muteins in accordance with the present invention include proteins encoded by a nucleic acid, such as DNA or RNA, which hybridizes to DNA or RNA, which encodes an IL6R/IL6 chimera, in accordance with the present invention, under stringent conditions. The term "stringent conditions" refers to hybridization and subsequent washing conditions, which those of ordinary skill in the art conventionally refer to as "stringent". See <nplcit id="ncit0035" npl-type="b"><text>Ausubel et al., Current Protocols in Molecular Biology, supra, Interscience, N.Y., §§6.3 and 6.4 (1987, 1992</text></nplcit>), and Sambrook et al. (<nplcit id="ncit0036" npl-type="b"><text>Sambrook, J. C., Fritsch, E. F., and Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY</text></nplcit>).</p><p id="p0040" num="0040">Without limitation, examples of stringent conditions include washing conditions 12-20°C below the calculated Tm of the hybrid under study in, e.g., 2 x SSC and 0.5% SDS for 5 minutes, 2 x SSC and 0.1% SDS for 15 minutes; 0.1 x SSC and 0.5% SDS at 37°C for 30-60 minutes and then, a 0.1 x SSC and 0.5% SDS at 68°C for 30-60 minutes. Those of ordinary skill in this art understand that stringency conditions also depend on the length of the DNA sequences, oligonucleotide probes (such as 10-40 bases) or mixed oligonucleotide probes. If mixed probes are used, it is preferable to use tetramethyl ammonium chloride (TMAC) instead of SSC. See Ausubel, supra.<!-- EPO <DP n="17"> --></p><p id="p0041" num="0041">Any such mutein preferably has a sequence of amino acids sufficiently duplicative of that of an EL6R/IL6 chimera, such as to have substantially similar, or even better, activity to IL6R/IL6 chimera.</p><p id="p0042" num="0042">Characteristic activity of IL6R/IL6 chimera is the capability of binding to the gp130. As long as the mutein has substantial capability of binding to gp 130 it can be considered to have substantially similar activity to IL6R/IL6 chimera. Thus, it can be determined whether any given mutein has at least substantially the same activity as IL6R/IL6 chimera by means of routine experimentation comprising subjecting hepatocytes to such mutein, and to determine whether or not it induces hepatocyte proliferation e.g. by measuring BrdU or labelled methionine uptake or just by counting the cells the cells vis-à-vis non treated control cells and cells treated with WT IL6R/IL6 chimera. An ELISA type assay for measuring the binding of IL-6R/IL-6 chimera to gp130 has been described in detail in example 7 on page 39 of <patcit id="pcit0005" dnum="WO9902552A"><text>WO 99/02552</text></patcit>.</p><p id="p0043" num="0043">A microtiter 96-well plate (Nunc) is coated with anti-human gp130 monoclonal antibody and 50 ng/ml of gpl3O (both from R &amp; D Systems, Minneapolis) is added. After washing in phosphate buffered saline, the IL-6R/IL-6 chimera is added in different wells at different concentrations ranging from 0.1 to 50 ng/ml. After incubation overnight at 40C, a rabbit polyclonal anti-IL-6R (<nplcit id="ncit0037" npl-type="s"><text>Oh et al., Cytokine, 8,401-409, 1996</text></nplcit>) is added, followed by goat antirabbit Ig conjugated with horseradish peroxidase, which is detected by colored reaction (Sigma, St. Louis).</p><p id="p0044" num="0044">As long as the mutant has substantial binding activity to gp130 it can be considered to have substantially similar activity to IL-6R/IL-6.</p><p id="p0045" num="0045">Thus it can be determined whether any given mutant has at least substantially the same activity as IL-6R/IL-6 chimera by means of routine experimentation comprising subjecting such mutant e.g. to a simple sandwich binding assay to determine whether or not it binds to an immobilized gp130 or soluble gp130 (extracellular fragment of gp130) as described in example 7 of <patcit id="pcit0006" dnum="WO9902552A"><text>WO 99/02552</text></patcit>.<!-- EPO <DP n="18"> --></p><p id="p0046" num="0046">In a preferred embodiment, any such mutein has at least 40% identity or homology with the sequence of mature IL-6R/IL-6 chimera. More preferably, it has at least 50%, at least 60%, at least 70%, at least 80% or, most preferably, at least 90% identity or homology thereto.</p><p id="p0047" num="0047">Identity reflects a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, determined by comparing the sequences. In general, identity refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of the two polynucleotides or two polypeptide sequences, respectively, over the length of the sequences being compared.</p><p id="p0048" num="0048">For sequences where there is not an exact correspondence, a "% identity" may be determined. In general, the two sequences to be compared are aligned to give a maximum correlation between the sequences. This may include inserting "gaps" in either one or both sequences, to enhance the degree of alignment. A % identity may be determined over the whole length of each of the sequences being compared (so-called global alignment), that is particularly suitable for sequences of the same or very similar length, or over shorter, defined lengths (so-called local alignment), that is more suitable for sequences of unequal length.</p><p id="p0049" num="0049">Methods for comparing the identity and homology of two or more sequences are well known in the art. Thus for instance, programs available in the Wisconsin Sequence Analysis Package, version 9.1 (Devereux J et all1984), for example the programs BESTFIT and GAP, may be used to determine the % identity between two polynucleotides and the % identity and the % homology between two polypeptide sequences. BESTFIT uses the "local homology" algorithm of Smith and Waterman (1981) and finds the best single region of similarity between two sequences. Other programs for determining identity and/or similarity between sequences are also known in the art, for instance the BLAST family of programs (Altschul S F et al, 1990, Altschul S F et al, 1997, accessible through the home page of the NCBI at www.ncbi.nhn.nih.gov) and FASTA (Pearson W R, 1990; Pearson 1988).<!-- EPO <DP n="19"> --></p><p id="p0050" num="0050">Muteins of IL-6R/IL-6 chimera, which can be used in accordance with the present invention, or nucleic acid coding therefore, include a finite set of substantially corresponding sequences as substitution peptides or polynucleotides which can be routinely obtained by one of ordinary skill in the art, without undue experimentation, based on the teachings and guidance presented herein.</p><p id="p0051" num="0051">Preferred changes for muteins in accordance with the present invention are what are known as "conservative" substitutions. Conservative amino acid substitutions of IL-6R/IL-6 chimera may include synonymous amino acids within a group which have sufficiently similar physicochemical properties that substitution between members of the group will preserve the biological function of the molecule (Grantham, 1974). It is clear that insertions and deletions of amino acids may also be made in the above-defined sequences without altering their function, particularly if the insertions or deletions only involve a few amino acids, e.g., under thirty, and preferably under ten, and do not remove or displace amino acids which are critical to a functional conformation, e.g., cysteine residues. Proteins and muteins produced by such deletions and/or insertions come within the purview of the present invention.</p><p id="p0052" num="0052">Preferably, the synonymous amino acid groups are those defined in Table A. More preferably, the synonymous amino acid groups are those defined in Table B; and most preferably the synonymous amino acid groups are those defined in Table C.
<tables id="tabl0001" num="0001"><table frame="none"><title><u>TABLE A</u></title><tgroup cols="2" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="30mm"/><colspec colnum="2" colname="col2" colwidth="50mm"/><thead><row><entry namest="col1" nameend="col2" align="left" valign="top">Preferred Groups of Synonymous Amino Acids</entry></row><row><entry valign="top">Amino Acid</entry><entry valign="top">Synonymous Group</entry></row></thead><tbody><row><entry>Ser</entry><entry>Ser, Thr, Gly, Asn</entry></row><row><entry>Arg</entry><entry>Arg, Gln, Lys, Glu, His</entry></row><row><entry>Leu</entry><entry>Ile, Phe, Tyr, Met, Val, Leu</entry></row><row><entry>Pro</entry><entry>Gly, Ala, Thr, Pro</entry></row><row><entry>Thr</entry><entry>Pro, Ser, Ala, Gly, His, Gln, Thr</entry></row><row><entry>Ala</entry><entry>Gly, Thr, Pro, Ala</entry></row><!-- EPO <DP n="20"> --><row><entry>Val</entry><entry>Met, Tyr, Phe, Ile, Leu, Val</entry></row><row><entry>Gly</entry><entry>Ala, Thr, Pro, Ser, Gly</entry></row><row><entry>Ile</entry><entry>Met, Tyr, Phe, Val, Leu, Ile</entry></row><row><entry>Phe</entry><entry>Trp, Met, Tyr, Ile, Val, Leu, Phe</entry></row><row><entry>Tyr</entry><entry>Trp, Met, Phe, Ile, Val, Leu, Tyr</entry></row><row><entry>Cys</entry><entry>Ser, Thr, Cys</entry></row><row><entry>His</entry><entry>Glu, Lys, Gln, Thr, Arg, His</entry></row><row><entry>Gln</entry><entry>Glu, Lys, Asn, His, Thr, Arg, Gln</entry></row><row><entry>Asn</entry><entry>Gln, Asp, Ser, Asn</entry></row><row><entry>Lys</entry><entry>Glu, Gln, His, Arg, Lys</entry></row><row><entry>Asp</entry><entry>Glu, Asn, Asp</entry></row><row><entry>Glu</entry><entry>Asp, Lys, Asn, Gln, His, Arg, Glu</entry></row><row><entry>Met</entry><entry>Phe, Ile, Val, Leu, Met</entry></row><row><entry>Trp</entry><entry>Trp</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0002" num="0002"><table frame="none"><title><u>TABLE B</u></title><tgroup cols="2" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="35mm"/><colspec colnum="2" colname="col2" colwidth="43mm"/><thead><row><entry namest="col1" nameend="col2" align="left" valign="top">More Preferred Groups of Synonymous Amino Acids</entry></row><row><entry valign="top">Amino Acid</entry><entry valign="top">Synonymous Group</entry></row></thead><tbody><row><entry>Ser</entry><entry>Ser</entry></row><row><entry>Arg</entry><entry>His, Lys, Arg</entry></row><row><entry>Leu</entry><entry>Leu, Ile, Phe, Met</entry></row><row><entry>Pro</entry><entry>Ala, Pro</entry></row><row><entry>Thr</entry><entry>Thr</entry></row><row><entry>Ala</entry><entry>Pro, Ala</entry></row><row><entry>Val</entry><entry>Val, Met, Ile</entry></row><row><entry>Gly</entry><entry>Gly</entry></row><row><entry>Ile</entry><entry>Ile, Met, Phe, Val, Leu</entry></row><row><entry>Phe</entry><entry>Met, Tyr, Ile, Leu, Phe</entry></row><row><entry>Tyr</entry><entry>Phe, Tyr</entry></row><row><entry>Cys</entry><entry>Cys, Ser</entry></row><row><entry>His</entry><entry>His, Gln, Arg</entry></row><row><entry>Gln</entry><entry>Glu, Gln, His</entry></row><row><entry>Asn</entry><entry>Asp, Asn</entry></row><!-- EPO <DP n="21"> --><row><entry>Lys</entry><entry>Lys, Arg</entry></row><row><entry>Asp</entry><entry>Asp, Asn</entry></row><row><entry>Glu</entry><entry>Glu, Gln</entry></row><row><entry>Met</entry><entry>Met, Phe, Ile, Val, Leu</entry></row><row><entry>Trp</entry><entry>Trp</entry></row></tbody></tgroup></table></tables>
<tables id="tabl0003" num="0003"><table frame="none"><title><u>TABLE C</u></title><tgroup cols="2" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="34mm"/><colspec colnum="2" colname="col2" colwidth="42mm"/><thead><row><entry namest="col1" nameend="col2" align="left" valign="top">Most Preferred Groups of Synonymous Amino Acids</entry></row><row><entry valign="top">Amino Acid</entry><entry valign="top">Synonymous Group</entry></row></thead><tbody><row><entry>Ser</entry><entry>Ser</entry></row><row><entry>Arg</entry><entry>Arg</entry></row><row><entry>Leu</entry><entry>Leu, Ile, Met</entry></row><row><entry>Pro</entry><entry>Pro</entry></row><row><entry>Thr</entry><entry>Thr</entry></row><row><entry>Ala</entry><entry>Ala</entry></row><row><entry>Val</entry><entry>Val</entry></row><row><entry>Gly</entry><entry>Gly</entry></row><row><entry>Ile</entry><entry>Ile, Met, Leu</entry></row><row><entry>Phe</entry><entry>Phe</entry></row><row><entry>Tyr</entry><entry>Tyr</entry></row><row><entry>Cys</entry><entry>Cys, Ser</entry></row><row><entry>His</entry><entry>His</entry></row><row><entry>Gln</entry><entry>Gln</entry></row><row><entry>Asn</entry><entry>Asn</entry></row><row><entry>Lys</entry><entry>Lys</entry></row><row><entry>Asp</entry><entry>Asp</entry></row><row><entry>Glu</entry><entry>Glu</entry></row><row><entry>Met</entry><entry>Met, Tie, Leu</entry></row><row><entry>Trp</entry><entry>Met</entry></row></tbody></tgroup></table></tables><!-- EPO <DP n="22"> --></p><p id="p0053" num="0053">Examples of production of amino acid substitutions in proteins which can be used for obtaining muteins of IL-6 polypeptides, for use in the present invention include any known method steps, such as presented in <patcit id="pcit0007" dnum="US4959314A"><text>US patents 4,959,314</text></patcit>, <patcit id="pcit0008" dnum="US4588585A"><text>4,588,585</text></patcit> and <patcit id="pcit0009" dnum="US4737462A"><text>4,737,462, to Mark et al</text></patcit>; <patcit id="pcit0010" dnum="US5116943A"><text>5,116,943 to Koths et al.</text></patcit>, <patcit id="pcit0011" dnum="US4965195A"><text>4,965,195 to Namen et al</text></patcit>; <patcit id="pcit0012" dnum="US4879111A"><text>4,879,111 to Chong et al</text></patcit>; and <patcit id="pcit0013" dnum="US5017691A"><text>5,017,691 to Lee et al</text></patcit>; and lysine substituted proteins presented in <patcit id="pcit0014" dnum="US4904584A"><text>US patent No. 4,904,584 (Shaw et al</text></patcit>).</p><p id="p0054" num="0054">The term "fused protein" refers to a polypeptide comprising an IL-6R/IL-6 chimera, or a mutein or fragment thereof, fused with another protein, which, e.g., has an extended residence time in body fluids. An IL-6R/IL-6 chimera may thus be fused to another protein, polypeptide or the like, e.g., an immunoglobulin or a fragment thereof.</p><p id="p0055" num="0055">"Functional derivatives" as used herein cover derivatives of IL-6R/IL-6 chimera, and their muteins and fused proteins, which may be prepared from the functional groups which occur as side chains on the residues or the N- or C-terminal groups, by means known in the art, and are included in the invention as long as they remain pharmaceutically acceptable, i.e..they do not destroy the activity of the protein which is substantially similar to the activity of IL-6R/IL-6 chimera, and do not confer toxic properties on compositions containing it.</p><p id="p0056" num="0056">These derivatives may, for example, include polyethylene glycol side-chains, which may mask antigenic sites and extend the residence of an IL-6R/IL-6 chimera in body fluids. Other derivatives include aliphatic esters of the carboxyl groups, amides of the carboxyl groups by reaction with ammonia or with primary or secondary amines, N-acyl derivatives of free amino groups of the amino acid residues formed with acyl moieties (e.g. alkanoyl or carbocyclic aroyl groups) or O-acyl derivatives of free hydroxyl groups (for example that of seryl or threonyl residues) formed with acyl moieties.<!-- EPO <DP n="23"> --></p><p id="p0057" num="0057">The term "salts" herein refers to both salts of carboxyl groups and to acid addition salts of amino groups of the IL-6R/L-6 chimera molecule or analogs thereof. Salts of a carboxyl group may be formed by means known in the art and include inorganic salts, for example, sodium, calcium, ammonium, ferric or zinc salts, and the like, and salts with organic bases as those formed, for example, with amines, such as triethanolamine, arginine or lysine, piperidine, procaine and the like. Acid addition salts include, for example, salts with mineral acids, such as, for example, hydrochloric acid or sulfuric acid, and salts with organic acids, such as, for example, acetic acid or oxalic acid. Of course, any such salts must retain the biological activity of IL-6R/IL-6 chimera, e.g. the ability to prevent or ameliorate CIPN and/or the ability to bind gp130.<br/>
"Isoforms" of IL-6R/IL-6 chimera are proteins capable of binding gp130 or fragment thereof, which may be produced by alternative splicing.</p><p id="p0058" num="0058">The term "circularly permuted derivatives" as used herein refers to a linear molecule in which the termini have been joined together, either directly or through a linker, to produce a circular molecule, and then the circular molecule is opened at another location to produce a new linear molecule with termini different from the termini in the original molecule. Circular permutations include those molecules whose structure is equivalent to a molecule that has been circularized and then opened. Thus, a circularly permuted molecule may be synthesized de novo as a linear molecule and never go through a circularization and opening step. The preparation of circularly permutated derivatives is described in <patcit id="pcit0015" dnum="WO9527732A"><text>WO95/27732</text></patcit>.</p><p id="p0059" num="0059">The IL-6 chimera may be selected from that described by <nplcit id="ncit0038" npl-type="s"><text>Chebath et al. (Eur Cytokine Netw. 1997 Dec;8(4):359-65. 1997</text></nplcit>), Hyper-intyerleukin-6 by Fischer et al. (<nplcit id="ncit0039" npl-type="s"><text>Fischer et al. Nat Biotechnol. 1997 Feb;15(2):142-5</text></nplcit>.) and the fused protein with direct bond of IL-6-receptor to IL-6 by <patcit id="pcit0016" dnum="WO0001731A"><text>Ekida Teiji, Ide Teruhiko (WO0001731</text></patcit>).</p><p id="p0060" num="0060">In a preferred embodiment of the invention, the IL-6 chimera is glycosylated at one or more sites.<!-- EPO <DP n="24"> --></p><p id="p0061" num="0061">A glycosylated form of an IL6R/IL6 chimera has been described in <patcit id="pcit0017" dnum="WO9902552A"><text>WO 99/02552</text></patcit> (<patcit id="pcit0018" dnum="IL9800321W"><text>PCT/IL98/00321</text></patcit>), which is the chimeric molecule highly preferred according to the invention. The IL6R/IL6 chimera described therein is a recombinant glycoprotein, which was obtained fusing the entire coding sequence of the naturally occurring soluble IL-6 receptor δ-vial (<nplcit id="ncit0040" npl-type="s"><text>Novick et al., J Chromatogr. 1990 Jun 27;510:331-7</text></nplcit>) to the entire coding sequence of mature naturally occurring IL-6, both from human origin.</p><p id="p0062" num="0062">The IL-6R/IL-6 chimera according to the invention may be produced in any adequate eukaryotic or procaryotic cell type, like yeast cells, insect cells, bacteria, and the like. It is preferably produced in mammalian cells, most preferably in genetically engineered CHO cells as described in <patcit id="pcit0019" dnum="WO9902552A"><text>WO 99/02552</text></patcit>.</p><p id="p0063" num="0063">In a further embodiment of the invention, the substance of the invention is not glycosylated. Advantageously, the molecule can then be produced in bacterial cells, which are not capable of synthesizing glycosyl residues, but usually have a high yield of produced recombinant protein. The production of non-glycosylated IL-6R/IL-6 chimera can be done, for example, in bacteria as described for the production of non-glycosylated IL-6 which has been described in detail in <patcit id="pcit0020" dnum="EP504751B1"><text>EP504751B1</text></patcit>.</p><p id="p0064" num="0064">In yet a further embodiment, the substance according to the invention comprises an immunoglobulin fusion, i.e. the molecules according to the invention are fused to all or a portion of an immunoglobulin. Methods for making immunoglobulin fusion proteins are well known in the art, such as the ones described in <patcit id="pcit0021" dnum="WO0103737A"><text>WO 01/03737</text></patcit>, for example. The person skilled in the art will understand that the resulting fusion protein of the invention retains the biological activity of the IL-6R/IL-6 chimera. The resulting fusion protein ideally has improved properties, such as an extended residence time in body fluids (half-life), increased specific activity, increased expression level, or facilitated purification of the fusion protein.<!-- EPO <DP n="25"> --></p><p id="p0065" num="0065">Preferably, the substance according to the invention is fused to the constant region of an Ig molecule. It may be fused to heavy chain regions, like the CH2 and CH3 domains of human IgG1, for example. Other isoforms of Ig molecules are also suitable for the generation of fusion proteins according to the present invention, such as isoforms IgG<sub>2</sub> or IgG<sub>4</sub>, or other Ig classes, like IgM or IgA, for example. Fusion proteins may be monomeric or multimeric, hetero- or homomultimeric.</p><p id="p0066" num="0066">Functional derivatives of the substance according to the invention may be conjugated to polymers in order to improve the properties of the protein, such as the stability, half-life, bioavailability, tolerance by the human body, or immunogenicity.</p><p id="p0067" num="0067">Therefore, a preferred embodiment of the invention relates to a functional derivative of the substance according to the invention comprising at least one moiety attached to one or more functional groups, which occur as one or more side chains on the amino acid residues.</p><p id="p0068" num="0068">A highly preferred embodiment relates to a substance of the invention linked to Polyethlyenglycol (PEG). PEGylation may be carried out by known methods, such as the ones described in <patcit id="pcit0022" dnum="WO9213095A"><text>WO 92/13095</text></patcit>, for example.</p><p id="p0069" num="0069">The definition of "pharmaceutically acceptable" is meant to encompass any carrier, which does not interfere with effectiveness of the biological activity of the active ingredient and that is not toxic to the host to which it is administered. For example, for parenteral administration, IL-6R/IL-6 chimera may be formulated in a unit dosage form for injection in vehicles such as saline, dextrose solution, serum albumin and Ringer's solution.</p><p id="p0070" num="0070">The medicament comprising the IL-6R/IL-6 chimera can be administered to a patient in need of administration thereof in a variety of ways. The routes of administration can be intraliver, intradermal, transdermal (e.g. in slow release formulations), intramuscular, intraperitoneal, intravenous, subcutaneous, oral, epidural, topical, and intranasal routes. Any other therapeutically efficacious route of administration can be used, for example absorption<!-- EPO <DP n="26"> --> through epithelial or endothelial tissues or by gene therapy wherein a DNA molecule encoding the IL-6R/IL-6 chimera is administered to the patient (e.g. via a vector), which causes the IL-6R/IL-6 chimera to be expressed and secreted in vivo. In addition the IL-6R/IL-6 chimera can be administered together with other components of biologically active agents such as pharmaceutically acceptable surfactants, excipients, carriers, diluents and vehicles.</p><p id="p0071" num="0071">For parenteral (e.g. intravenous, subcutaneous, intramuscular) administration, IL-6R/IL-6 chimera can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable parenteral vehicle (e.g. water, saline, dextrose solution) and additives that maintain isotonicity (e.g. mannitol) or chemical stability (e.g. preservatives and buffers). The formulation is sterilized by commonly used techniques.</p><p id="p0072" num="0072">An "effective amount" refers to an amount of the active ingredients that is sufficient to affect the course and the severity of the diseases described above, leading to the reduction or remission of such pathology. The effective amount will depend on the route of administration and the condition of the patient.</p><p id="p0073" num="0073">The dosage administered, as single or multiple doses, to an individual will vary depending upon a variety of factor, including IL-6R/IL-6 chimera pharmacokinetic properties, the route of administration, patient conditions and characteristics (sex, age, body weight, health, size), extent of symptoms, concurrent treatments, frequency of treatment and the effect desired. Adjustment and manipulation of established dosage ranges are well within the ability of those skilled.</p><p id="p0074" num="0074">The invention relates to the use an IL-6R/IL-6 chimera or a mutein thereof in the manufacture of a medicament for the treatment and/or prevention of CIPN.</p><p id="p0075" num="0075">The dose of IL-6R/IL-6 chimera can be administered before during and/or after chemotherapy. The dose of IL-6R/IL-6 chimera can be administered prophylacticaly before CIPN is established or for treating established CIPN.<!-- EPO <DP n="27"> --></p><p id="p0076" num="0076">Having now fully described this invention, it will be appreciated by those skilled in the art that the same can be performed within a wide range of equivalent parameters, concentrations and conditions without departing from the scope of the invention and without undue experimentation.</p><p id="p0077" num="0077">While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications.</p><p id="p0078" num="0078">Reference to known method steps, conventional methods steps, known methods or conventional methods is not any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.<!-- EPO <DP n="28"> --></p><p id="p0079" num="0079">The present invention will now be described in more detail in the following nonlimiting examples and the accompanying drawings.</p><heading id="h0006"><b>EXAMPLES</b></heading><heading id="h0007"><b>Example 1: In vitro effects of IL-6R/IL-6 chimera on dorsal root ganglia cells intoxicated by vincristine.</b></heading><p id="p0080" num="0080">EL-6R/IL-6 chimera (Chebath et al, 1997) was used to explore prevention against vincristine intoxication in vitro. For this purpose, cultures of dorsal root ganglia (DRG) from mouse embryos (day E17) in which neuronal outgrowth was stimulated by Nerve Growth Factor (NGF), were subsequently exposed to 10 nM vincristine which induces a progressive axonal degeneration process (<nplcit id="ncit0041" npl-type="s"><text>Wang et al, J Neuropathol Exp Neurol. 2000 Jul;59(7):599-606</text></nplcit>.). After 2 days, a considerable loss of axons in the DRG outgrowth was evident after immunostaining for βIII-tubulin (<figref idrefs="f0001">Fig. 1</figref>, panels B versus A). Addition of IL-6R/IL-6 during the treatment by vincristine prevented axonal degeneration (panel C). Neurodegeneration was further examined by monitoring the proteolytic activation of caspase-3, which denotes the early stages of apoptosis in various neuropathies (<nplcit id="ncit0042" npl-type="s"><text>Russell et<!-- EPO <DP n="29"> --> al, Neurobiol Dis. 1999 Oct;6(5):347-63</text></nplcit>.). Positive reaction to antibodies against activated caspase-3 was observed in the DRG cultures treated for 5 days with vincristine (panel D). However, when IL-6R/IL-6 was present during the vincristine treatment there was virtually no caspase-3 activation (panel E).</p><heading id="h0008"><b>Example 2: In vitro effects of IL-6R/IL-6 chimera on dorsal root ganglia cells intoxicated by vincristine.</b></heading><p id="p0081" num="0081">I was further investigated whether the IL-6R/IL-6 could have neural regenerative effects by adding IL-6R/IL-6 after the action of vincristine had taken place. One such experiment carried out with DRG of E18.5 embryos from IL-6 deficient mice (IL-6 -/-) is shown in <figref idrefs="f0002">Figure 2</figref>. Cultures in which the axonal network was formed in the presence of NGF for 5 days were either continued for another 11 days without or with IL-6R/IL-6 (panel A and B, respectively), or treated for 5 days by vincristine at which time vincristine was removed and culture continued for 6 more days (panels C-F). The extensive degeneration of the axonal network was still observed 6 days after vincristine was removed (panel C) but when IL-6R/IL-6 was added, after vincristine removal, a significant re-growth- of the axons- was - observed- (panel D). In parallel m cultures immunostained for glial fibrillary acidic protein (GFAP), the addition of IL-6R/IL-6 was found to produce a marked re-growth of glial cells (panel F) as compared to the control cultures 6 days after vincristine removal (panel E). In several similar experiments, the neural regenerative effects of IL-6R/IL-6 were seen in DRG cultures from IL-6+/+ mice, and were apparent already two days after IL-6R/IL-6 addition (not shown). These experiments indicate that IL-6R/IL-6 chimera has promotes regeneration of neural and glial cells when added after exposure to the chemotherapeutic agent.</p><heading id="h0009"><b>Example 3: Dorsal Root Ganglia (DRG) cultures, vincristine and IL-6R/IL-6 treatments.</b></heading><!-- EPO <DP n="30"> --><p id="p0082" num="0082">DRGs were prepared as detailed before (Haggiag et al, 1999, 2001) from embryos of (C57BL/6x129Sv) Fl mice. In some experiments, corresponding IL-6-/- mutant mice were used (Mendel et al, 1998). The DRGs were seeded onto glass coverslips (precoated with a solution of 20 µg/ml poly-D-lysine, 250 µg/ml fibronectin), which were placed in 12-well Costar plates. The regular culture medium was 0.5 ml DMEM/F12 medium with 1% N2 supplement, 10% fetal bovine serum, 2% horse serum, 1.4 mM glutamine (all from Gibco/Invitrogen) and 50 ng/ml NGF (2.5S; Alomone Labs, Jerusalem, Israel). Cultures were maintained at 37°C, 5% CO2 and medium replaced every third day. On day 5, some of the wells were supplemented with 10 nM vincristine sulfate salt (Sigma, St Louis, MO), or vincristine together with 200 ng/ml pure recombinant IL-6R/IL-6 , prepared as described (Chebath et al, 1997). After 2-5 days, the cultures were fixed in 4% paraformaldehyde, 10 minutes at room temperature (RT), washed in PBS, then treated with 0.5% Triton X-100 and 10% normal goat serum in PBS for 3 minutes at RT and washed 3 times with 1% NGS. For studying the curative effects, similar DRG cell cultures treated on day 5 with vincristine (5 nM) were washed on day 10 to remove vincristine and replenished with the above regular medium either alone or supplemented with 200 ng/ml IL-6R/IL-6 and culture continued for 6 more days before fixation.</p><heading id="h0010"><b>Example 4: Immunostaining</b></heading><p id="p0083" num="0083">Immunostaining was overnight at RT with mouse monoclonal antibody TUJ1 anti-neuronal βIII-tubulin antibody (Covance, Berkeley, CA; MMS-435P, diluted 1:500) and Ab-4 anti-caspase-3 activated form (Oncogene Research Products, San Diego, CA; AM65, diluted 1:200). Second antibodies were goat anti-mouse IgG conjugated with Alexa Fluor 488 (Molecular Probes, Eugene, OR; A11029, diluted 1:200) for tubulin, and Cy3-conjugated affinity purified goat anti-mouse IgG, F (ab') 2 fragment specific (Jackson ImmunoResearch Laboratories, West Grove, PA; diluted 1:600) for caspase. Mouse monoclonal anti-GFAP -Cy3 conjugate antibody (Sigma-Aldrich; C9205, diluted 1:400) was applied 1hour at RT. After washing in PBS, coverslips were mounted in Mowiol (Calbiochem, LaJolla, CA) and photographed in an Olympus IX-70 FLA microscope with a DVC-1310C digital camera (DVS, Austin, TX) and images processed by Photoshop.</p></description><claims mxw-id="PCLM56979728" lang="DE" load-source="patent-office"><!-- EPO <DP n="35"> --><claim id="c-de-01-0001" num="0001"><claim-text>Verwendung einer IL6R/IL6-Chimäre oder eines Muteins davon bei der Herstellung eines Medikaments zur Vorbeugung und/oder Behandlung von Chemotherapieinduzierter peripherer Neuropathie (CIPN), wobei es sich bei dem Chemotherapiemittel um ein Vinca-Alkaloid handelt, und wobei ferner das Mutein eine Aminosäuresequenz, die von der Aminosäuresequenz der IL6R/IL6-Chimäre durch Deletion oder Substitution eines oder mehrerer Aminosäurereste(s) der natürlich vorkommenden Komponenten der IL6R/IL6-Chimäre oder durch Addition eines oder mehrerer Aminosäurereste(s) zu der ursprünglichen Sequenz der IL6R/IL6-Chimäre abgeleitet ist, aufweist und fähig ist, an gp130 zu binden.</claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Verwendung gemäß Anspruch 1, wobei die periphere Neuropathie durch Vinblastin, Vincristin oder ein Gemisch davon verursacht ist.</claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Verwendung gemäß Anspruch 1 oder 2, wobei die IL6R/IL6-Chimäre oder das Mutein davon an einer oder mehreren Stellen glykosyliert ist.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Verwendung gemäß Anspruch 1 oder 2, wobei die IL6R/IL6-Chimäre oder das Mutein davon nichtglykosyliert ist.</claim-text></claim><claim id="c-de-01-0005" num="0005"><claim-text>Verwendung gemäß einem der vorhergehenden Ansprüche, wobei das Mutein mindestens eine Einheit umfasst, die an einer oder mehreren funktionellen Gruppen befestigt ist.</claim-text></claim><claim id="c-de-01-0006" num="0006"><claim-text>Verwendung gemäß Anspruch 5, wobei es sich bei der Einheit um eine Polyethyleneinheit handelt.</claim-text></claim><claim id="c-de-01-0007" num="0007"><claim-text>Verwendung gemäß einem der Ansprüche 1 bis 6, wobei das Medikament eine Zelle umfasst, die eine IL6R/IL6-Chimäre oder ein Mutein davon exprimiert.</claim-text></claim><claim id="c-de-01-0008" num="0008"><claim-text>Verwendung gemäß einem der Ansprüche 1 bis 7, wobei das Medikament einen Expressionsvektor umfasst, der die kodierende Sequenz einer IL6R/IL6-Chimäre oder eines Muteins davon umfasst.<!-- EPO <DP n="36"> --></claim-text></claim><claim id="c-de-01-0009" num="0009"><claim-text>Verwendung gemäß Anspruch 8, wobei es sich bei dem Vektor um einen lentiviralen Vektor handelt.</claim-text></claim><claim id="c-de-01-0010" num="0010"><claim-text>Verwendung nach einem der Ansprüche 1 bis 9, wobei das Medikament gegebenenfalls einen pharmazeutisch verträglichen Träger umfasst.</claim-text></claim><claim id="c-de-01-0011" num="0011"><claim-text>Verwendung nach Anspruch 10, wobei es sich bei dem Patienten um einen Hochrisikopatienten handelt, ausgewählt aus Patienten, die an Diabetes, AIDS, erblichen Neuropathien leiden, und Patienten, die einer frühen Behandlung mit neurotoxischen Arzneimitteln unterworfen wurden.</claim-text></claim><claim id="c-de-01-0012" num="0012"><claim-text>Verwendung nach einem der Ansprüche 10 bis 11, wobei der Verabreichungsweg des Medikaments aus intrahepatisch, intradermal, intraplantar, transdermal, intramuskulär, intraperitoneal, intravenös, subkutan, oral, epidural, topisch und intranasal ausgewählt ist.</claim-text></claim><claim id="c-de-01-0013" num="0013"><claim-text>Verwendung einer IL6R/IL6-Chimäre oder eines Muteins davon, gegebenenfalls zusammen mit einem pharmazeutisch verträglichen Träger, bei der Herstellung eines Medikaments zum Erhöhen der Dosis eines chemotherapeutischen Mittels bei einem Patienten, wobei es sich bei dem Chemotherapiemittel um ein Vinca-Alkaloid handelt, und wobei ferner das Mutein eine Aminosäuresequenz, die von der Aminosäuresequenz der IL6R/IL6-Chimäre durch Deletion oder Substitution eines oder mehrerer Aminosäurereste(s) der natürlich vorkommenden Komponenten der IL6R/IL6-Chimäre oder durch Addition eines oder mehrerer Aminosäurereste(s) zu der ursprünglichen Sequenz der IL6R/IL6-Chimäre abgeleitet ist, aufweist und fähig ist, an gp130 zu binden.</claim-text></claim><claim id="c-de-01-0014" num="0014"><claim-text>Verwendung gemäß Anspruch 13, wobei das Medikament entweder vor, während und/oder nach dem Chemotherapiemittel verabreicht wird.</claim-text></claim><claim id="c-de-01-0015" num="0015"><claim-text>Pharmazeutische Zusammensetzung, umfassend eine Kombination einer IL6R/IL6-Chimäre oder eines Muteins davon und eines chemotherapeutischen Mittels, wobei es sich bei dem Chemotherapiemittel um ein Vinca-Alkaloid handelt, und wobei ferner das Mutein eine Aminosäuresequenz, die von der Aminosäuresequenz der IL6R/IL6-Chimäre durch Deletion oder Substitution eines oder mehrerer Aminosäurereste(s) der natürlich vorkommenden Komponenten der IL6R/IL6-Chimäre oder durch Addition eines oder mehrerer Aminosäurereste(s) zu der<!-- EPO <DP n="37"> --> ursprünglichen Sequenz der IL6R/IL6-Chimäre abgeleitet ist, aufweist und fähig ist, an gp130 zu binden.</claim-text></claim><claim id="c-de-01-0016" num="0016"><claim-text>Pharmazeutische Zusammensetzung gemäß Anspruch 15, wobei das Vinca-Alkaloid aus Vinblastin, Vincristin oder einem Gemisch davon ausgewählt ist.</claim-text></claim><claim id="c-de-01-0017" num="0017"><claim-text>Pharmazeutische Zusammensetzung gemäß Anspruch 15 oder 16, ferner umfassend ein zusätzliches Arzneimittel, ausgewählt aus Antioxidantien, PKC-Inhibitoren und neuroprotektiven Mitteln.</claim-text></claim><claim id="c-de-01-0018" num="0018"><claim-text>Pharmazeutische Zusammensetzung gemäß Anspruch 17, wobei das zusätzliche Arzneimittel aus Glutamat, Pyridoxin, Gamma-Linolsäure, Vitamin B1, Vitamin B2 Isoaxonin, Gangliosid und NGF ausgewählt ist.</claim-text></claim><claim id="c-de-01-0019" num="0019"><claim-text>IL6R/IL6-Chimäre oder Mutein davon zur Verwendung bei der Vorbeugung und/oder Behandlung von Chemotherapie-induzierter peripherer Neuropathie (CIPN), wobei es sich bei dem Chemotherapiemittel um ein Vinca-Alkaloid handelt, und wobei ferner das Mutein eine Aminosäuresequenz, die von der Aminosäuresequenz der IL6R/IL6-Chimäre durch Deletion oder Substitution eines oder mehrerer Aminosäurereste(s) der natürlich vorkommenden Komponenten der IL6R/IL6-Chimäre oder durch Addition eines oder mehrerer Aminosäurereste(s) zu der ursprünglichen Sequenz der IL6R/IL6-Chimäre abgeleitet ist, aufweist und fähig ist, an gp130 zu binden.</claim-text></claim><claim id="c-de-01-0020" num="0020"><claim-text>IL6R/IL6-Chimäre oder Mutein davon zur Verwendung beim Erhöhen der Dosis eines chemotherapeutischen Mittels bei einem Patienten, wobei es sich bei dem Chemotherapiemittel um ein Vinca-Alkaloid handelt, und wobei ferner das Mutein eine Aminosäuresequenz, die von der Aminosäuresequenz der IL6R/IL6-Chimäre durch Aminosäure-Deletion, Insertion, Addition oder Substitution eines oder mehrerer Aminosäurereste(s) der natürlich vorkommenden Komponenten der IL6R/IL6-Chimäre oder durch Addition eines oder mehrerer Aminosäurereste(s) zu der ursprünglichen Sequenz der IL6R/IL6-Chimäre abgeleitet ist, aufweist und fähig ist, an gp130 zu binden.</claim-text></claim></claims><claims mxw-id="PCLM56979729" lang="EN" load-source="patent-office"><!-- EPO <DP n="31"> --><claim id="c-en-01-0001" num="0001"><claim-text>Use of an IL6R/IL6 chimera, or a mutein thereof, in the manufacture of a medicament for the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN), wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>The use according to claim 1, wherein the peripheral neuropathy is caused by vinblastine, vincristine or a mixture thereof.</claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>The use according to claim 1 or 2, wherein the IL6R/IL6 chimera or mutein thereof is glycosylated at one or more sites.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>The use according to claim 1 or 2, wherein the IL6R/IL6 chimera or mutein thereof is non-glycosylated.</claim-text></claim><claim id="c-en-01-0005" num="0005"><claim-text>The use according to any of the preceding claims, wherein the mutein comprises at least one moiety attached to one or more functional groups.</claim-text></claim><claim id="c-en-01-0006" num="0006"><claim-text>The use according to claim 5, wherein the moiety is a polyethylene moiety.</claim-text></claim><claim id="c-en-01-0007" num="0007"><claim-text>The use according to any one of claims 1 to 6, wherein the medicament comprises a cell expressing an IL6R/IL6 chimera or a mutein thereof.<!-- EPO <DP n="32"> --></claim-text></claim><claim id="c-en-01-0008" num="0008"><claim-text>The use according to any one of claims 1 to 7, wherein the medicament comprises an expression vector comprising the coding sequence of an IL6R/IL6 chimera or mutein thereof.</claim-text></claim><claim id="c-en-01-0009" num="0009"><claim-text>The use according to claim 8, wherein the vector is a lentiviral vector.</claim-text></claim><claim id="c-en-01-0010" num="0010"><claim-text>The use of any of claims 1 to 9, wherein the medicament optionally comprises a pharmaceutically acceptable carrier.</claim-text></claim><claim id="c-en-01-0011" num="0011"><claim-text>The use of claim 10, wherein the patient is a high-risk patient selected from patients suffering from diabetes, AIDS, hereditary neuropathies and patients subjected to early treatment with neurotoxic drugs.</claim-text></claim><claim id="c-en-01-0012" num="0012"><claim-text>The use of any of claims 10 to 11, wherein the administration route of the medicament is selected from intraliver, intradermal, intraplantar, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, oral, epidural, topical, and intranasal.</claim-text></claim><claim id="c-en-01-0013" num="0013"><claim-text>Use of an IL6R/IL6 chimera or a mutein thereof, optionally together with a pharmaceutically acceptable carrier, in the manufacture of a medicament for increasing the dose of a chemotherapeutic agent in a patient, wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</claim-text></claim><claim id="c-en-01-0014" num="0014"><claim-text>The use according to claim 13 wherein the medicament is administered either before, during, and/or after the chemotherapy agent.<!-- EPO <DP n="33"> --></claim-text></claim><claim id="c-en-01-0015" num="0015"><claim-text>A pharmaceutical composition comprising a combination of an IL6R/IL6 chimera or a mutein thereof and a chemotherapeutic agent wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</claim-text></claim><claim id="c-en-01-0016" num="0016"><claim-text>The pharmaceutical composition according to claim 15, wherein the vinca alkaloid is selected from vinblastine, vincristine or a mixture thereof.</claim-text></claim><claim id="c-en-01-0017" num="0017"><claim-text>The pharmaceutical composition according to claim 15 or 16, further comprising an additional drug selected from antioxidants, PKC inhibitors and neuroprotective agents.</claim-text></claim><claim id="c-en-01-0018" num="0018"><claim-text>The pharmaceutical composition according to claim 17, wherein the additional drug is selected from glutamate, pyridoxine, gamma-linoleic acid, vitamin B1, vitamin B2, isoaxonine, ganglioside and NGF.</claim-text></claim><claim id="c-en-01-0019" num="0019"><claim-text>An IL6R/IL6 chimera, or a mutein thereof, for use in the prevention and/or treatment of chemotherapy induced peripheral neuropathy (CIPN), wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by deletion or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</claim-text></claim><claim id="c-en-01-0020" num="0020"><claim-text>An an IL6R/IL6 chimera, or a mutein thereof, for use in increasing the dose of a chemotherapeutic agent in a patient, wherein the chemotherapy agent is a vinca alkaloid, and further wherein the mutein has an amino acid sequence derived from the amino acid sequence of the IL6R/IL6 chimera by<!-- EPO <DP n="34"> --> amino acid deletion, insertion, addition or substitution of one or more amino acid residue(s) of the naturally occurring components of the IL6R/IL6 chimera or by addition of one or more amino acid residue(s) to the original sequence of the IL6R/IL6 chimera and is capable of binding to gp130.</claim-text></claim></claims><claims mxw-id="PCLM56979730" lang="FR" load-source="patent-office"><!-- EPO <DP n="38"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Utilisation d'une chimère IL6R/IL6, ou d'une mutéine de celle-ci, dans la fabrication d'un médicament destiné à la prévention et/ou au traitement d'une neuropathie périphérique induite par une chimiothérapie (CIPN), où l'agent chimiothérapeutique est un vinca-alcaloïde, et en outre où la mutéine a une séquence d'acides aminés dérivée de la séquence d'acides aminés de la chimère IL6R/IL6 par délétion ou substitution d'un ou de plusieurs résidus d'acides aminés des composants existant à l'état naturel de la chimère IL6R/IL6 ou par addition d'un ou de plusieurs résidus d'acides aminés à la séquence d'origine de la chimère IL6R/IL6 et est capable de se lier à la gp130.</claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Utilisation selon la revendication 1, où la neuropathie périphérique est provoquée par la vinblastine, la vincristine ou un mélange de celles-ci.</claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Utilisation selon la revendication 1 ou 2, où la chimère IL6R/IL6 ou une mutéine de celle-ci est glycosylée au niveau d'un ou de plusieurs sites.<!-- EPO <DP n="39"> --></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Utilisation selon la revendication 1 ou 2, où la chimère IL6R/IL6 ou une mutéine de celle-ci est non glycosylée.</claim-text></claim><claim id="c-fr-01-0005" num="0005"><claim-text>Utilisation selon l'une quelconque des revendications précédentes, où la mutéine comprend au moins un radical fixé à un ou plusieurs groupes fonctionnels.</claim-text></claim><claim id="c-fr-01-0006" num="0006"><claim-text>Utilisation selon la revendication 5, où le radical est un radical de polyéthylène.</claim-text></claim><claim id="c-fr-01-0007" num="0007"><claim-text>Utilisation selon l'une quelconque des revendications 1 à 6, où le médicament comprend une cellule exprimant une chimère IL6R/IL6 ou une mutéine de celle-ci.</claim-text></claim><claim id="c-fr-01-0008" num="0008"><claim-text>Utilisation selon l'une quelconque des revendications 1 à 7, où le médicament comprend un vecteur d'expression comprenant la séquence codante d'une chimère IL6R/IL6 ou d'une mutéine de celle-ci.</claim-text></claim><claim id="c-fr-01-0009" num="0009"><claim-text>Utilisation selon la revendication 8, où le vecteur est un vecteur lentiviral.</claim-text></claim><claim id="c-fr-01-0010" num="0010"><claim-text>Utilisation selon l'une quelconque des revendications 1 à 9, où le médicament comprend éventuellement un support pharmaceutiquement acceptable.</claim-text></claim><claim id="c-fr-01-0011" num="0011"><claim-text>Utilisation selon la revendication 10, où le patient est un patient à haut risque, choisi parmi des patients souffrant de diabète, du SIDA, de neuropathies héréditaires et des patients soumis à un traitement précoce avec des médicaments neurotoxiques.</claim-text></claim><claim id="c-fr-01-0012" num="0012"><claim-text>Utilisation selon l'une quelconque des revendications 10 et 11, où la voie d'administration du médicament est choisie parmi les voies intrahépatique, intradermique, intraplantaire, transdermique,<!-- EPO <DP n="40"> --> intramusculaire, intrapéritonéale, intraveineuse, sous-cutanée, orale, épidurale, topique et intranasale.</claim-text></claim><claim id="c-fr-01-0013" num="0013"><claim-text>Utilisation d'une chimère IL6R/IL6 ou d'une mutéine de celle-ci, éventuellement conjointement avec un support pharmaceutiquement acceptable, dans la fabrication d'un médicament destiné à l'augmentation de la dose d'un agent chimiothérapeutique chez un patient, où l'agent chimiothérapeutique est un vinca-alcaloïde, et en outre où la mutéine a une séquence d'acides aminés dérivée de la séquence d'acides aminés de la chimère IL6R/IL6 par délétion ou substitution d'un ou de plusieurs résidus d'acides aminés des composants existant à l'état naturel de la chimère IL6R/IL6 ou par addition d'un ou de plusieurs résidus d'acides aminés à la séquence d'origine de la chimère IL6R/IL6 et est capable de se lier à la gp130.</claim-text></claim><claim id="c-fr-01-0014" num="0014"><claim-text>Utilisation selon la revendication 13, où le médicament est administré soit avant, soit durant, et/soit après l'agent chimiothérapeutique.</claim-text></claim><claim id="c-fr-01-0015" num="0015"><claim-text>Composition pharmaceutique comprenant une combinaison d'une chimère IL6R/IL6 ou d'une mutéine de celle-ci et d'un agent chimiothérapeutique, où l'agent chimiothérapeutique est un vinca-alcaloïde, et en outre où la mutéine a une séquence d'acides aminés dérivée de la séquence d'acides aminés de la chimère IL6R/IL6 par délétion ou substitution d'un ou de plusieurs résidus d'acides aminés des composants existant à l'état naturel de la chimère IL6R/IL6 ou par addition d'un ou de plusieurs résidus d'acides aminés à la séquence d'origine de la chimère IL6R/IL6 et est capable de se lier à la gp130.<!-- EPO <DP n="41"> --></claim-text></claim><claim id="c-fr-01-0016" num="0016"><claim-text>Composition pharmaceutique selon la revendication 15, où le vinca-alcaloïde est choisi parmi la vinblastine, la vincristine ou un mélange de celles-ci.</claim-text></claim><claim id="c-fr-01-0017" num="0017"><claim-text>Composition pharmaceutique selon la revendication 15 ou 16, comprenant en outre un médicament supplémentaire choisi parmi des antioxydants, des inhibiteurs de PKC et des agents neuroprotecteurs.</claim-text></claim><claim id="c-fr-01-0018" num="0018"><claim-text>Composition pharmaceutique selon la revendication 17, dans laquelle le médicament supplémentaire est choisi parmi le glutamate, la pyridoxine, l'acide gamma-linoléique, la vitamine B1, la vitamine B2, l'isoaxonine, le ganglioside et le NGF.</claim-text></claim><claim id="c-fr-01-0019" num="0019"><claim-text>Chimère IL6R/IL6, ou une mutéine de celle-ci, pour une utilisation dans la prévention et/ou le traitement d'une neuropathie périphérique induite par une chimiothérapie (CIPN), où l'agent chimiothérapeutique est un vinca-alcaloïde, et en outre où la mutéine a une séquence d'acides aminés dérivée de la séquence d'acides aminés de la chimère IL6R/IL6 par délétion ou substitution d'un ou de plusieurs résidus d'acides aminés des composants existant à l'état naturel de la chimère IL6R/IL6 ou par addition d'un ou de plusieurs résidus d'acides aminés à la séquence d'origine de la chimère IL6R/IL6 et est capable de se lier à la gp130.</claim-text></claim><claim id="c-fr-01-0020" num="0020"><claim-text>Chimère IL6R/IL6, ou une mutéine de celle-ci, pour une utilisation visant à augmenter la dose d'un agent chimiothérapeutique chez un patient, où l'agent chimiothérapeutique est un vinca-alcaloïde, et en outre où la mutéine a une séquence d'acides aminés dérivée de<!-- EPO <DP n="42"> --> la séquence d'acides aminés de la chimère IL6R/IL6 par délétion, insertion, addition ou substitution d'un ou de plusieurs résidus d'acides aminés des composants existant à l'état naturel de la chimère IL6R/IL6 ou par addition d'un ou de plusieurs résidus d'acides aminés à la séquence d'origine de la chimère IL6R/IL6 et est capable de se lier à la gp130.</claim-text></claim></claims><drawings mxw-id="PDW16668948" load-source="patent-office"><!-- EPO <DP n="43"> --><figure id="f0001" num="1A,1B,1C,1D,1E,1F"><img id="if0001" file="imgf0001.tif" wi="143" he="124" img-content="drawing" img-format="tif"/></figure><!-- EPO <DP n="44"> --><figure id="f0002" num="2A,2B,2C,2D,2E,2F"><img id="if0002" file="imgf0002.tif" wi="153" he="199" img-content="drawing" img-format="tif"/></figure></drawings><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
